Ashley Gallagher is an editor at Pharmacy Times®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.
CDC, FDA Announce 77,000 Additional Doses for Nirsevimab as Infant Treatment of RSV
November 22nd 2023Additional doses for the prophylaxis of respiratory syncytial virus will immediately be distributed to physicians and hospitals through commercial channels and the Vaccines for Children Program.
Read More
Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
November 21st 2023Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.
Read More
Extended-Release Buprenorphine Found Well-Tolerated for Fentanyl Opioid Use Disorder
November 21st 2023Eligible individuals with opioid use disorder using fentanyl received a single 4 mg dose of transmucosal buprenorphine followed by the extended-release buprenorphine 300 mg injection after approximately 1 hour.
Read More
FDA Approves Enzalutamide for Nonmetastatic Castration-Sensitive Prostate Cancer
November 17th 2023The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.
Read More
FDA Approves Capivasertib With Fulvestrant for PIK3CA/AKT1/PTEN Alterations Breast Cancer
November 17th 2023Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.
Read More
FDA Approves Defencath for Catheter-Related Infections for Those With Kidney Failure
November 15th 2023Taurolidine and heparin (Defencath; CorMedix) is indicated to reduce catheter-related bloodstream infections for adults with kidney failure who are receiving chronic hemodialysis via central venous catheter
Read More
Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers
November 9th 2023Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.
Read More
Study: Risk of Atrial Fibrillation Remains High After 3 Years, Including Those With Heart Failure
November 6th 2023Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.
Read More